Waters Peptide Multi-Attribute Method for BioAccord System Boosts Innovator
May 11 2021 Waters Corporation (NYSE:WAT) has introduced a new peptide multi-attribute method (MAM) workflow for the Waters™ BioAccord™ LC-MS System, enabling drug development, manufacturing, and QC scientists to monitor efficacy and safety through the analysis of critical quality attributes (CQAs) of monoclonal antibodies (mAbs) and other protein-based drugs. “The BioAccord System moves attribute-based monitoring out of centralised MS labs and into the hands of more scientists in regulated and quality control laboratories who may not have extensive experience ...
Source: labmate-online.com